A Study of Combined Onabotulinumtoxin A and Hyaluronic Acid Filler for the Treatment of Enlarged Facial Pores.
Abstract
[INTRODUCTION] Enlarged facial pores are a common cosmetic concern caused by excessive sebum production, visible hair shafts, and a reduction in skin elasticity, leading to a decrease in skin quality and overall appearance. Various treatment modalities have been explored to address this issue. This study focuses on the efficacy and safety of combining Onabotulinumtoxin A (OnaBoNT-A) and hyaluronic acid filler (HA filler) to target enlarged facial pores in Asians.
[MATERIALS AND METHODS] This study aimed to compare the efficacy and safety of OnaBoNT-A monotherapy in combination with HA filler for the treatment of enlarged facial pores. This study was a prospective, randomized, single-blinded, split-face, controlled trial that enrolled 32 subjects with visibly enlarged pores on both cheeks. One side of the face received intradermal injections of OnaBoNT-A, while the other side received OnaBoNT-A in combination with intradermal hyaluronic acid filler injection. The outcomes were measured by pore volume, visual assessment, pain score, improvement score, and side effects at various time intervals up to 24 weeks.
[RESULTS] This study investigated the effects of onaBoNT-A monotherapy or in combination with HA filler on facial pore size and skin roughness. The results showed that both sides exhibited a reduction in pore volume and skin roughness over time, but the side treated with onaBoNT-A monotherapy had a slightly better improvement than the combination side at the 6-month follow-up. Subjects with histories of facial oiliness were more likely to respond to onaBoNT-A monotherapy, while those without histories of facial oiliness were more likely to respond to the side treated with combined treatment. The most common adverse events were erythema, bruising, and edema, which were more frequent on the combination side. Additionally, 18 subjects (56.25%) experienced a palpable lump on the combination side, which resolved in most cases within a few months.
[CONCLUSION] BoNT-A and HA dermal filler had a role in reducing pore size. Nonetheless, individuals with enlarged pores who exhibited beneficial effects to botulinum toxin injection typically had a background of facial oiliness. Adverse incidents like dermal edema and palpable nodules were observed, underscoring the significance of meticulous patient selection and accurate injection technique.
[MATERIALS AND METHODS] This study aimed to compare the efficacy and safety of OnaBoNT-A monotherapy in combination with HA filler for the treatment of enlarged facial pores. This study was a prospective, randomized, single-blinded, split-face, controlled trial that enrolled 32 subjects with visibly enlarged pores on both cheeks. One side of the face received intradermal injections of OnaBoNT-A, while the other side received OnaBoNT-A in combination with intradermal hyaluronic acid filler injection. The outcomes were measured by pore volume, visual assessment, pain score, improvement score, and side effects at various time intervals up to 24 weeks.
[RESULTS] This study investigated the effects of onaBoNT-A monotherapy or in combination with HA filler on facial pore size and skin roughness. The results showed that both sides exhibited a reduction in pore volume and skin roughness over time, but the side treated with onaBoNT-A monotherapy had a slightly better improvement than the combination side at the 6-month follow-up. Subjects with histories of facial oiliness were more likely to respond to onaBoNT-A monotherapy, while those without histories of facial oiliness were more likely to respond to the side treated with combined treatment. The most common adverse events were erythema, bruising, and edema, which were more frequent on the combination side. Additionally, 18 subjects (56.25%) experienced a palpable lump on the combination side, which resolved in most cases within a few months.
[CONCLUSION] BoNT-A and HA dermal filler had a role in reducing pore size. Nonetheless, individuals with enlarged pores who exhibited beneficial effects to botulinum toxin injection typically had a background of facial oiliness. Adverse incidents like dermal edema and palpable nodules were observed, underscoring the significance of meticulous patient selection and accurate injection technique.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 재료 | ha
|
히알루론산 | dict | 4 | |
| 시술 | hyaluronic acid filler
|
필러 주입술 | dict | 3 | |
| 시술 | ha filler
|
필러 주입술 | dict | 3 | |
| 재료 | hyaluronic acid
|
히알루론산 | dict | 3 | |
| 시술 | onabotulinumtoxin
|
보툴리눔독소 주사 | dict | 2 | |
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 | |
| 시술 | dermal filler
|
필러 주입술 | dict | 1 | |
| 해부 | sebum
|
scispacy | 1 | ||
| 해부 | skin
|
scispacy | 1 | ||
| 해부 | facial pores
|
scispacy | 1 | ||
| 해부 | intradermal
|
scispacy | 1 | ||
| 해부 | pores
|
scispacy | 1 | ||
| 합병증 | cheeks
|
scispacy | 1 | ||
| 합병증 | erythema
|
scispacy | 1 | ||
| 합병증 | edema
|
scispacy | 1 | ||
| 약물 | Onabotulinumtoxin A
|
C2719767
onabotulinumtoxinA
|
scispacy | 1 | |
| 약물 | cheeks
|
C0007966
Cheek structure
|
scispacy | 1 | |
| 약물 | [INTRODUCTION] Enlarged facial pores
|
scispacy | 1 | ||
| 약물 | intradermal hyaluronic acid
|
scispacy | 1 | ||
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 질환 | oiliness
|
scispacy | 1 | ||
| 질환 | erythema
|
C0041834
Erythema
|
scispacy | 1 | |
| 질환 | bruising
|
C0009938
Contusions
|
scispacy | 1 | |
| 질환 | edema
|
C0013604
Edema
|
scispacy | 1 | |
| 질환 | dermal edema
|
scispacy | 1 | ||
| 질환 | nodules
|
scispacy | 1 | ||
| 기타 | hair shafts
|
scispacy | 1 | ||
| 기타 | HA dermal filler
|
scispacy | 1 | ||
| 기타 | patient
|
scispacy | 1 |
MeSH Terms
Humans; Hyaluronic Acid; Botulinum Toxins, Type A; Female; Dermal Fillers; Adult; Middle Aged; Male; Cosmetic Techniques; Face; Single-Blind Method; Prospective Studies; Skin; Skin Aging; Treatment Outcome
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.